Semaglutide 1.0 mg and 2.0 mg Once-Weekly Doses Directly Compared in Type 2 Diabetes Patients

Type 2 Diabetes (T2D) is a chronic metabolic disorder characterized by insulin resistance and impaired insulin secretion, leading to hyperglycemia. Current standard-of-care often involves oral anti-diabetic medications like metformin and sulphonylureas, but many patients still struggle to achieve optimal glycemic control. Glucagon-like peptide-1 receptor (GLP-1R) agonists, such as semaglutide, have emerged as effective treatments, improving glycemic control and often leading to weight loss. This study aims to further refine semaglutide dosing strategies to optimize patient outcomes by comparing two established doses.

This 49-week, randomized study will compare two subcutaneous (SC) doses of semaglutide ( 1.0 mg and 2.0 mg) administered once weekly in participants with Type 2 Diabetes (T2D) already on stable doses of sulphonylurea and/or metformin. Participants will be randomly assigned to receive either semaglutide 1.0 mg or semaglutide 2.0 mg via weekly SC injection. The study involves approximately 9 clinic visits and 2 phone calls, with primary endpoints likely focusing on glycemic control (e.g., HbA1c) and safety, assessed via blood tests and eye tests. Female participants capable of pregnancy will undergo urine pregnancy tests 11 times.